适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial TreatmentProstatic NeoplasmsCTIS2023-503919-15-00Eli Lilly & Co.42
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancerung Cancer or Breast CancerCTIS2023-506788-32-00Eli Lilly & Co.1
招募中
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants with Type 1 Diabetes Mellitus.Type 1 Diabetes MellitusCTIS2023-510365-10-00Eli Lilly & Co.70
招募中
1 期
A Randomised Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3876602 in Healthy Participants.HealthyMedDRA version: 21.1Level: PTClassification code: 10053643Term: Neurodegenerative disorder Class: 100000004852CTIS2023-504838-21-00Eli Lilly & Co.69
进行中（未招募）
1 期
First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor ß in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])Metabolic dysfunction-associated steatotic liver disease, Crohn’s disease, Primary Sclerosing CholangitisMedDRA version: 24.1Level: LLTClassification code: 10086076Term: Fibrostenotic Crohn´s disease Class: 100000004848MedDRA version: 20.0Level: PTClassification code: 10076331Term: Steatohepatitis Class: 100000004871MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-506555-15-00Antaros Medical AB30